The review summarizes the most recent advances in stem cell and regenerative approaches to treat kidney injury, and highlights areas of active controversy. Over the past year, a number of findings have been reported that have brought this field much closer to clinical translation.
INTRODUCTION
Stem cell and regenerative medicine approaches to kidney injury are among the most exciting concepts to have emerged in nephrology over the past decade. Although progress has been slow until recently, the field now appears poised to advance rapidly. I will review the discoveries driving this innovation, but first summarize some fundamental principles of kidney regenerative biology already established and widely agreed upon. These include the discovery that multipotent renal stem cells exist in the developing mammalian kidney; that adult nephron has a robust but not inexhaustible capacity to repair after acute injury; and the revelation that lower vertebrates such as zebrafish are capable of generating entirely new nephrons from an adult kidney stem cell population.
During nephrogenesis, the kidney develops from intermediate mesoderm through a process of reciprocal inductive signals exchanged between the ureteric bud and the cap mesenchyme. Cells from cap mesenchyme -itself derived from intermediate mesoderm -condense to form the pretubular aggregate and subsequently undergo mesenchymal-toepithelial transition to form the renal vesicle. This further develops into an increasingly complicated structure ultimately forming the entire nephron [1] .
Elegant studies have shown conclusively that the cap mesenchyme contains multipotent kidney progenitors that both self-renew and differentiate, forming all the epithelial cells found along the nephron except for collecting duct [2] [3] [4] . These findings have provided important markers, such as Six2 (sine oculis homeobox homolog) or OSR1 (odd-skipped related-1), to aim for when inducing embryonic stem cells toward kidney progenitor fates, as discussed below.
Another established concept is that proximal tubule epithelia undergo proliferative expansion after acute injury to repair acute damage [5, 6] . Epithelial cell proliferation helps restore cells lost to apoptosis or necrosis during the insult [7] . Whereas the burst of proliferation in proximal tubules after injury is widely accepted, understanding the signals that drive epithelial proliferation is now a major focus of acute kidney injury (AKI) research. Importantly, the cellular source of these dividing cells remains unresolved.
Finally, although mammals cannot grow new nephrons after kidney development ceases, one of the most exciting recent findings has been the indisputable demonstration that lower vertebrates are able to regenerate entire nephrons after injury. Elger et al. [8] first provided strong histologic evidence that the elasmobranch skate kidney could generate new nephrons after partial nephrectomy. But the elegant work of Davidson and colleagues provided indisputable evidence that adult kidney stem cells exist in zebrafish, and can be serially transplanted [9] . Collectively, these studies raise an important question: Why have lower vertebrates retained a capacity for postnatal nephron neogenesis that mammals have lost? A better understanding of this issue will provide critical insight into kidney regeneration.
In the following sections, I outline four areas of ongoing controversy in the field of regenerative nephrology. Although not comprehensive, for example I will not cover glomerular regeneration [10, 11] , this list includes controversies that are especially relevant to AKI.
DO TUBULAR STEM CELLS EXIST?
A basic prerequisite for the design of a stem cell or regenerative approach to kidney injury is a clear understanding of how the adult kidney repairs itself normally. Yet this remains a contentious and controversial area. Two competing theories have arisen to explain the origin of proliferating tubular epithelia after acute injury: a stem or progenitor cell generates new epithelia, or fully differentiated epithelia dedifferentiate, re-enter the cell cycle and generate new epithelial cells through self-duplication. Support for both theories exists.
Arguing for the epithelial stem cell theory, a variety of candidate progenitor cells have been described. Genetic fate mapping of nFatC1þ cells in AKI suggests that these may represent an intratubular progenitor population [12] . Importantly, individual proximal tubule cells in humans that express vimentin, CD24 and CD133 have been recently identified, and these putative progenitor cells are present both in parietal epithelium and also scattered throughout the proximal tubule. When isolated ex vivo, these cells can form spheres and clonally expand, and they ameliorate AKI and apparently contribute to epithelial lineage in experimental models [13,14 && , 15, 16] . Recently, LGR5 (leucinerich repeat-containing G-protein coupled receptor 5) was shown by lineage analysis to mark a distal tubule progenitor population during development, providing further support to the notion that epithelial progenitors could exist in adult kidney [17 & ]. Other characteristics including side population, label retention and clonality have been reported to enrich for putative intratubular epithelial stem cells [18] [19] [20] [21] .
On the other hand, we have shown using a genetic lineage analysis strategy that no extratubular stem or progenitor population migrates into the tubule during repair from AKI [22] . Moreover, the traditional model for AKI repair holds that epithelial repair after injury occurs by dedifferentiation and proliferation of surviving epithelial cells [6, 23] . Support from this model derives from the finding that differentiated proximal tubule cells are poised in G1, ready to re-enter the cycle after injury [24] . Because our genetic approach could not distinguish a dedifferentiation model from a stem cell model of epithelial repair, we have also tracked the proliferative history of proximal tubule epithelia after acute injury using sequential pulses of thymidine analog. This study showed that cell division at different time-points during repair is by separate random fractions of the total epithelium. These results argue strongly that repair is not through a minority population of stem cells that proliferate rapidly, but rather all surviving epithelial cells have an equivalent capacity for repair [25] . This result, however, has actually been interpreted by others to support a stem cell-based repair mechanism, reasoning that tubular progenitors preferentially survive and therefore represent the dominant population among surviving cells, and thus divide only once or twice during repair [26, 27] .
KEY POINTS
Whether or not adult kidney harbors a proximal tubule stem cell population remains an unresolved controversy.
The use of MSCs to prevent AKI is already in phase II clinical trials, but important gaps exist in our understanding of how these unique cells exert their reno-protective effects.
Research into the use of embryonic stem cells and iPS cells as inexhaustible sources of differentiated cell types has grown rapidly in the past year and promises to be one of the most active areas in kidney stem cell research in the near future.
Thus it remains unclear whether an intratubular progenitor may exist or not. Importantly, Smeets et al. [28 && ] have recently shown that kidney injury molecule-1 (Kim-1) is coexpressed with human vimentinþCD24þCD133þ tubule cells. Vimentin and Kim-1 are tubular injury markers [29, 30] , and these authors observed no basal expression of either marker in healthy rat kidney, but up-regulation of both proteins after injury. Therefore, they argue that vimentinþCD24þCD133þ cells do not reflect a preexisting progenitor population, but rather reflect transient dedifferentiation [28 && ]. This is a provocative concept because it may explain the consistent observations of CD24þCD133þ cells in humans, suggesting that these may reflect individual cells undergoing dedifferentiation, perhaps due to local stresses or homeostatic repair. Resolution of this debate, however, will require definitive evidence from genetic lineage analysis in vivo. The two possible mechanisms of epithelial repair are summarized in Fig. 1 . Studies are currently underway in several laboratories, so expect more developments in this rapidly moving field.
WHAT IS THE ROLE OF MESENCHYMAL STEM CELL-BASED THERAPIES FOR TREATMENT OF ACUTE KIDNEY INJURY?
As a regenerative approach already in translation, with mesenchymal stem cell (MSC)-based clinical trials for treatment of kidney disease underway, MSCs have attracted intense attention for their potential therapeutic use [31] . MSCs act in a paracrine fashion to exert anti-inflammatory, pro-repair, immunomodulatory effects [32] . These are accomplished through secretion of soluble factors including growth factors and angiogenic cytokines. MSCs also secrete exosomes containing microRNAs that mediate part of the beneficial effects of these cells after injection [33,34 & ]. A series of careful studies have proven that MSCs do not integrate into kidney parenchyma, and in fact reside in kidney only transiently after injection [35] . Nevertheless, MSCs have been shown to ameliorate a wide variety of kidney diseases, from AKI to chronic kidney disease to glomerular disease [36] .
Unique among stem cell approaches to kidney disease, a phase I clinical trial has recently been completed testing the safety of MSCs in patients undergoing on-pump cardiac surgery at high risk for developing AKI. This study enrolled 16 patients, and administered escalating doses of MSCs into the distal thoracic aorta. Study participants were followed up for 6 months, and no specific adverse events were reported. A secondary objective of the trial was to compare patients who received MSCs with matched historical controls who had not received stem cell therapy. This analysis suggests that MSCs afford early and late kidney protection, as well as decreased hospital length of stay [37] . These results have allowed a privately held company, Allocure, to initiate a phase II trial designed as a randomized, double-blind, placebo-controlled multicenter trial to assess the efficacy of MSCs in approximately 200 cardiac surgery patients (NCT01602328, www.allocure.com).
Despite the compelling progress that these two clinical trials demonstrate, unanswered questions remain concerning the how best to apply MSCs to kidney disease. A central problem is the therapeutic mechanism, which remains poorly defined. MSCs do not engraft in kidney when injected intraarterially, and when injected intravenously they embolize in lung [38] . Therefore, these studies are not cell transplantation, but rather infusion of cells that exert effects through paracrine mechanisms -so this is not a stem cell replacement therapy, because the cells do not engraft. This implies that if we can identify the bioactive substances secreted by MSCs, the infusion of these alone, without cells, would be just as good or better. Whether MSCs release bioactive molecules in a temporal sequence -in effect responding to a changing environment -is not known. In preclinical studies, however, conditioned media from MSCs protected kidneys from acute injury just as well as injection of the cells did [39] . Clearly, an incomplete understanding of the mechanism of action of this therapy is no reason not to pursue these clinical trials, but more basic research into MSC biology and kidney protection is required.
HOW CAN EMBRYONIC STEM CELLS AND INDUCED PLURIPOTENT CELLS BE USED TO TREAT KIDNEY INJURY?
The ability to direct the differentiation of embryonic stem cells to any cell type of interest is recognized as a powerful and inexhaustible source for cell replacement therapies. Yamanaka's Nobel prize-winning discovery that mature somatic cells can be reprogrammed to become pluripotent stem cells [induced pluripotent stem cells (iPSCs)] by expression of four transcription factors has shifted paradigms and accelerated the clinical development of cell therapies [40, 41] . Because iPSCs can be generated easily from any patient, they offer the promise of disease modeling, toxicity testing and personalized cell therapies without fear of immunologic rejection.
Progress towards generating kidney cell types from embryonic stem cells or iPSCs has been notably slow compared to other fields, until recently. Full protocols for the derivation of hepatocytes, neurons and cardiac myocytes were established years ago [42] [43] [44] , and these have catalyzed important new discoveries such as the possibility of completing a clinical trial in a Petri dish [45 && ,46] . No efficient protocol has existed in kidney, but recent progress gives encouragement that this field is about to break open.
Several groups have demonstrated that exposure of embryonic stem cells or iPS cells to factors required for renal specification, such as retinoic acid, activin A and bone morphogenic proteins(BMPs), does induce differentiation into renal lineage cells, including intermediate mesoderm, as well as individual apparently differentiated cells, such as proximal tubule or podocyte [47] [48] [49] [50] [51] . However, a limitation to these efforts has been the relatively inefficient differentiation process, which can take weeks, as well as the low yield of differentiated cells. The field has also been held back by the absence of a robust assay to test the functional capacity of these cells, in addition to their expression of typical markers. Recently, Little's group have described a novel reaggregation assay, in which embryonic mouse kidney is disaggregated, then reaggregated along with exogenous cell populations, and subsequently cultured [52 & ]. This in-vitro system provides a powerful platform on which to assess the differentiation and incorporation potential of cells derived from embryonic stem cells or iPSC cultures, and should stimulate further development of directed differentiation protocols.
Mae et al. . Notably, they also showed incorporation of these cells into differentiated tubular structures during reaggregation organ culture, albeit at a relatively low frequency of 5%. This is an important finding, one that is sure to stimulate further refinements in the directed differentiation of embryonic stem cells and iPS cells to kidney fates.
Apart from generating more efficient and robust differentiation protocols, an additional challenge in this field is to understand the stability of the differentiation state achieved. This will require a deeper understanding of the mechanisms driving and maintaining renal cell fates which remain obscure. Rather than induce the differentiation of kidney cell types from multipotent progenitors, an important new question in the field is whether direct reprogramming, from one differentiated cell type to another, can achieve the same goals as directed differentiation. This concept was first shown by Zhou et al. [54] in reprogramming pancreatic exocrine cells to pancreatic beta cells. Very recently, the first instance of kidney reprogramming was reported. This elegant study screened various combinations of transcription factors and identified a specific combination of six that were able to reprogram epithelial cells into Six2þ nephron progenitors [55 & ]. These cells were fully able to differentiate into epithelial cells in a reaggregation assay. Whether created through differentiation or reprogramming, new strategies for achieving integration of these cells within the kidney parenchyma will be required. Certainly one promising use is in tissue engineering, as discussed below.
ARE TISSUE ENGINEERING APPROACHES VIABLE AS A RENAL REPLACEMENT STRATEGY?
At the beginning of the stem cell era, there was enthusiasm for the concept of growing a new kidney, either in a dish, or through transplantation of embryonic tissue into a host (reviewed in [56] ). But the challenges to growing a functional kidney soon became evident, dampening enthusiasm. Unlike single-cell disorders like diabetes or amyotrophic lateral sclerosis, the challenge with kidney failure is the creation of a functional organ composed of about 30 cell types organized in a precise three-dimensional structure. Even after this, how can the host blood supply integrate into the graft? How to plumb in the collecting system to existing ureters? Over the past 2 years, however, substantial progress in tissue engineering approaches has been made that suggest that many of these problems are at least tractable, though far from being solved.
Historically, two different strategies have been employed to engineer a kidney: combining synthetic components with cells in a hybrid device, and generating a transplantable kidney entirely from cells. Whereas hybrid devices continue to develop, they will be only briefly summarized here. Humes et al. [57] successfully designed the renal assist device (RAD), consisting of a conventional hemofilter in series with a bioreactor containing thousands of hollow microfibers lined by kidney epithelial cells. After filtration in the conventional hemofilter, the ultrafiltrate passes through the lumen of the bioreactor while the blood is pumped through the extracapillary space. Although not in direct contact with the cells, the blood is modified by the cells, including reduction in pro-inflammatory cytokines and other mediators (reviewed in [57] ). The RAD made it into clinical trials, as far as a phase IIa safety and preliminary efficacy trial, but ran into manufacturing troubles and the phase IIb trial was not completed [58, 59] . Despite the suspended clinical trial of the RAD, these devices continue to be developed, including portable or even implantable ones, and this field remains promising for treatment of end-stage renal disease.
A strategy combing renal progenitor cells with a biocompatible scaffold, rather than an engineered synthetic one, has recently been reported and represents a remarkable technical feat. Song et al. [60 && ] decellurized an isolated rat kidney with a detergent solution to reveal the extracellular matrix, including vasculature, glomerular basement membrane and tubular basement membranes. They subsequently devised methods to seed the vasculature with cultured endothelial cells, and the tubules and glomeruli with rat kidney progenitor cells isolated from embryonic rat kidney. These single cells contained progenitors for all tubule components as well as interstitium. After reseeding of the kidney scaffold, cells differentiated and expressed appropriate cell-cell contacts and markers of differentiated cells. When delivered perfusate, these regenerated kidneys produced urine and filtrate that suggested active absorptive and secretory function. Most remarkably, when transplanted orthotopically in rat, with renal artery and vein anastomosed to the regenerated kidney, it also produced a filtrate with less glycosuria and albuminuria than simple decellurized kidneys, strong evidence suggesting the regenerated kidney restored macromolecular sieving and glucose reabsorption. This study focuses attention on the importance of kidney scaffolding in providing cues for progenitors to differentiate appropriately. It will be particularly interesting to combine this decellularization approach with other sources of kidney progenitors, such as directed differentiation or reprogramming. Figure 2 summarizes the ways that stem cell biology and artificial kidneys may be combined to provide a source for transplantable engineered kidneys to patients.
CONCLUSION
The recent advances in stem cell and regenerative approaches to treating kidney injury show remarkable promise. Although it is not clear to what extent some of these approaches are truly 'regenerative', since they may actually target endogenous repair programs, there is no question that we are much closer now to new and innovative approaches to treat kidney disease than at any other point in the stem cell era.
